Artivion, Inc. (NYSE:AORT) SVP Marshall S. Stanton Sells 26,132 Shares

Artivion, Inc. (NYSE:AORT - Get Free Report) SVP Marshall S. Stanton sold 26,132 shares of the company's stock in a transaction that occurred on Friday, June 13th. The shares were sold at an average price of $28.44, for a total transaction of $743,194.08. Following the completion of the transaction, the senior vice president now owns 79,200 shares of the company's stock, valued at $2,252,448. This trade represents a 24.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Artivion Stock Up 3.6%

AORT traded up $1.04 during trading hours on Tuesday, hitting $29.77. 396,113 shares of the company's stock were exchanged, compared to its average volume of 336,346. Artivion, Inc. has a 1-year low of $21.97 and a 1-year high of $32.33. The stock's 50-day moving average is $26.83 and its two-hundred day moving average is $27.46. The stock has a market cap of $1.27 billion, a price-to-earnings ratio of -59.54 and a beta of 1.62. The company has a quick ratio of 3.95, a current ratio of 5.53 and a debt-to-equity ratio of 1.08.

Artivion (NYSE:AORT - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported $0.06 EPS for the quarter, missing analysts' consensus estimates of $0.12 by ($0.06). The firm had revenue of $98.98 million during the quarter, compared to analyst estimates of $94.81 million. Artivion had a negative net margin of 5.49% and a positive return on equity of 3.63%. Sell-side analysts predict that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Analyst Ratings Changes

AORT has been the subject of several research analyst reports. Canaccord Genuity Group initiated coverage on shares of Artivion in a report on Tuesday. They issued a "buy" rating and a $35.00 price target for the company. JMP Securities reiterated a "market outperform" rating and issued a $33.00 price target on shares of Artivion in a report on Tuesday, May 6th. Stifel Nicolaus reduced their target price on shares of Artivion from $33.00 to $30.00 and set a "buy" rating for the company in a report on Tuesday, February 25th. Citizens Jmp upgraded shares of Artivion to a "strong-buy" rating in a report on Tuesday, May 6th. Finally, Needham & Company LLC restated a "buy" rating and set a $32.00 target price on shares of Artivion in a report on Tuesday, May 6th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Artivion has a consensus rating of "Buy" and an average target price of $32.00.

Institutional Trading of Artivion

Large investors have recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC lifted its stake in Artivion by 236.7% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company's stock valued at $32,000 after acquiring an additional 786 shares during the last quarter. Legacy Advisors LLC bought a new position in shares of Artivion in the first quarter valued at about $28,000. MCF Advisors LLC raised its position in shares of Artivion by 109.3% in the first quarter. MCF Advisors LLC now owns 1,176 shares of the company's stock valued at $29,000 after purchasing an additional 614 shares during the period. Arcadia Investment Management Corp MI bought a new position in shares of Artivion in the fourth quarter valued at about $43,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Artivion in the fourth quarter valued at about $64,000. Institutional investors and hedge funds own 86.37% of the company's stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.